IRVINE, Calif. and HERSTAL, Belgium, June 28, 2016 (GLOBE NEWSWIRE) --
MDxHealth SA (Euronext: MDXH.BR), announced today that it has secured
reimbursement coverage agreement for its SelectMDx(TM) for Prostate Cancer
test with Fortified Provider Network. This agreement serves all 50 states,
offering patients greater access to MDxHealth's liquid biopsy test.
Fortified Provider Network (FPN), is a direct-contracted preferred provider
network with 5 million covered lives across the US. Under the agreement,
SelectMDx for Prostate Cancer will be made available for members of
Fortified's network, which includes self-funded employer groups, insurance
carriers and regional and local provider networks that process end-user
patient claims.
"This agreement with FPN will significantly expand coverage for SelectMDx to
patients across the United States," said Dr. Jan Groen, Chief Executive
Officer of MDxHealth. "This marks another milestone in our commercial strategy
for this newly launched test and in our mission to provide the urology
community validated and impactful molecular diagnostic solutions, which
address unmet medical needs for cancer patients."
About Fortified Provider Network
Fortified Provider Network ("FPN") is a national direct-contracted preferred
provider network. FPN's select provider network is utilized by self-funded
employer groups, insurance carriers and regional and local provider networks
that process end-user patient claims. FPN offers the utilization of its
network to its more than 200 payor clients and members who, in turn, are able
to capitalize on the discounted fee schedules FPN has negotiated with its
healthcare providers. FPN contracts with physicians, hospitals, ancillary
facilities, mid-level providers and other specialty healthcare providers who
have the option of participating in one or more of our products (group health,
workers compensation or auto liability).